A candidate antibody drug for prevention of malaria.

"the entire set of unique natively paired igg sequences ( n = 28672) from pbs ( n = 32948) of rtss vaccines ( n = 45) are available at https://zenodo org/records/10019777 . data availability accession numbers for all paired heavy- and light-chain igg sequences recombinantly expressed were provided through bankit: 2749610: or662637"

"code availability the custom code used in r for bootstrap analyses is available at https://github com/expositum/rts_s_cspbinding_vs_protection .; custom code used in the titrationanalysis tool for spr analyses is available at https://github com/dukechsi/titrationanalysis ."

"Competing interests W.H.R. owns equity in, serves as a consultant to and is a member of the Board of Directors of Atreca, Inc. K.L.W., S.G., K.S.W. and S.M.L. own equity in, and are employed by, Atreca, Inc. D.E.E. and M.W. own equity in, and serve as consultants to, Atreca, Inc. G.C. and D.K. own equity in Atreca, Inc. C.S., P.S., S.Z.J. and R.R.K. are employed by Just – Evotec Biologics. E.J. owns equity in, and is employed by, GSK. U.W.-R. is employed by BioNTech. J.G. owns equity in, is employed by and is a member of the Board of Directors of Centivax, Inc. Y.C.T. owns equity in Atreca, Inc. and is employed by Nuevocor Pte. Ltd. K.L.W., S.M.L., R.R.K. and D.E.E. are coinventors on patent applications filed by Atreca, Inc. that include antibodies to CSP. The remaining authors declare no competing interests."

"We thank J. Kirchner for scientific, business and leadership contributions and for manuscript review and editing; L. M. Stuart for scientific, business and leadership contributions; L. Shackelton for scientific, business and project management contributions; D. Hopkins for project management contributions; K. Andrews and H. Liu for scientific and project management contributions; R. Scott Miller for manuscript review and editing; T. A. Serafini for corporate support and business and scientific contributions; S. E. Gould for manuscript review, editing, figure improvements and scientific contributions; S. Mudrak for project management support, manuscript review and editing; R. H. C. Huntwork and G. Q. Horn for binding analyses of engineered variants; and A. Birkett and C. Gerard for manuscript review and editing. F.Z., Y.F.-G. and S.M.-T. thank the Insectary Core of the Malaria Research Institute and the Bloomberg Philanthropies for continued support. This work was supported by the Bill and Melinda Gates Foundation (BMGF) at Atreca, Inc. and at Just—Evotec Biologics, Inc. (no. INV-008062), with grants to F.Z. (INV-001763) and G.D.T. (nos. OPP1151372 and INV008612), and by PATH-MVI with a grant to F.Z. BMGF contributed to experimental design and interpretation of results. We also acknowledge editorial assistance from M. Hyde and J. McGuire at BOLDSCIENCE, Inc. The contents of this publication are solely the responsibility of the authors and do not represent the official views of BMGF."